CN109563130A - 用于治疗神经退行性疾病的tdp-43线粒体定位抑制剂 - Google Patents

用于治疗神经退行性疾病的tdp-43线粒体定位抑制剂 Download PDF

Info

Publication number
CN109563130A
CN109563130A CN201780028382.0A CN201780028382A CN109563130A CN 109563130 A CN109563130 A CN 109563130A CN 201780028382 A CN201780028382 A CN 201780028382A CN 109563130 A CN109563130 A CN 109563130A
Authority
CN
China
Prior art keywords
tdp
seq
mitochondria
mouse
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780028382.0A
Other languages
English (en)
Chinese (zh)
Inventor
王兴龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of CN109563130A publication Critical patent/CN109563130A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201780028382.0A 2016-04-07 2017-04-07 用于治疗神经退行性疾病的tdp-43线粒体定位抑制剂 Pending CN109563130A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662319580P 2016-04-07 2016-04-07
US62/319,580 2016-04-07
US201662328484P 2016-04-27 2016-04-27
US62/328,484 2016-04-27
PCT/US2017/026675 WO2017177178A1 (en) 2016-04-07 2017-04-07 Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
CN109563130A true CN109563130A (zh) 2019-04-02

Family

ID=60000683

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780028382.0A Pending CN109563130A (zh) 2016-04-07 2017-04-07 用于治疗神经退行性疾病的tdp-43线粒体定位抑制剂

Country Status (9)

Country Link
US (2) US11124553B2 (enExample)
EP (1) EP3440094B1 (enExample)
JP (1) JP2019513752A (enExample)
KR (1) KR20180132807A (enExample)
CN (1) CN109563130A (enExample)
AU (1) AU2017248353A1 (enExample)
CA (1) CA3020344A1 (enExample)
SG (1) SG11201808829VA (enExample)
WO (1) WO2017177178A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113450336A (zh) * 2021-07-01 2021-09-28 维柯基科技(上海)有限公司 一种多孔荧光微阵列图像的处理方法、装置、计算机设备及计算机可读存储介质
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645557B1 (en) 2017-06-28 2024-10-23 The Cleveland Clinic Foundation Treatment of nervous system injury and neurodegenerative disorders and related conditions
CN113683703B (zh) * 2020-05-18 2023-08-15 中国人民解放军陆军军医大学第二附属医院 一种hTERT靶向物及其用途
WO2021247893A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Bicyclic heteroaromatic amide compounds and uses thereof
CN114057858B (zh) 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
KR102488166B1 (ko) 2020-09-24 2023-01-13 재단법인대구경북과학기술원 Ｈｄａｃ６의 ｔｄｐ－４３ 단백질병증 예방 또는 치료제로서의 용도
JP6961278B1 (ja) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 生体試料中のｔｄｐ−４３を測定する方法及び装置
KR20240133923A (ko) * 2023-02-28 2024-09-05 (주)케어젠 펩타이드 복합체를 유효성분으로 포함하는 항노화용 조성물
KR102859015B1 (ko) 2023-07-20 2025-09-12 충북대학교 산학협력단 ｃ­Ａｂｌ에 의한 ＴＤＰ­４３의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229837A1 (en) * 2003-05-15 2004-11-18 Yijuang Chern Treatment of neurodegenerative diseases
US20110065600A1 (en) * 2008-02-01 2011-03-17 The Washington University Sequences associated with tdp-43 proteinopathies and methods of using the same
WO2013192298A1 (en) * 2012-06-22 2013-12-27 The Scripps Research Institute Apoptosis biomarkers
US20150045248A1 (en) * 2012-02-28 2015-02-12 National University Corporation Tokyo University Of Agriculture And Technology Method for identifying disease associated with abundance of tdp-43 in cell

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
GB9723824D0 (en) * 1997-11-11 1998-01-07 Actinova Ltd Cytostatic agents
EP1305333A4 (en) 2000-07-31 2006-04-12 Active Motif PEPTIDE-MEDIATED DELIVERY OF MOLECULES IN CELLS
EP1915621A2 (en) * 2005-07-01 2008-04-30 Arbor Vita Corporation Methods and compositions for diagnosis and treatment of viral and bacterial infections
JP5519291B2 (ja) 2006-12-06 2014-06-11 トーマス・ジェファーソン・ユニバーシティ Ｈｉｖ−１感染症のためのペプチド及び治療法
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US9926353B2 (en) * 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US9017672B2 (en) * 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229837A1 (en) * 2003-05-15 2004-11-18 Yijuang Chern Treatment of neurodegenerative diseases
US20110065600A1 (en) * 2008-02-01 2011-03-17 The Washington University Sequences associated with tdp-43 proteinopathies and methods of using the same
US20150045248A1 (en) * 2012-02-28 2015-02-12 National University Corporation Tokyo University Of Agriculture And Technology Method for identifying disease associated with abundance of tdp-43 in cell
WO2013192298A1 (en) * 2012-06-22 2013-12-27 The Scripps Research Institute Apoptosis biomarkers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
张巍 等: "TDP-43蛋白与运动神经元病", 《中国神经免疫学和神经病学杂质》 *
王晓良: "《应用分子药理学》", 30 September 2015, 中国协和医科大学出版社 *
陈晓光: "《药理学研究的新思路与新靶点》", 30 September 2012, 中国协和医科大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113450336A (zh) * 2021-07-01 2021-09-28 维柯基科技(上海)有限公司 一种多孔荧光微阵列图像的处理方法、装置、计算机设备及计算机可读存储介质
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途

Also Published As

Publication number Publication date
KR20180132807A (ko) 2018-12-12
CA3020344A1 (en) 2017-10-12
JP2019513752A (ja) 2019-05-30
WO2017177178A1 (en) 2017-10-12
EP3440094A4 (en) 2019-03-20
EP3440094A1 (en) 2019-02-13
US11124553B2 (en) 2021-09-21
EP3440094B1 (en) 2021-02-17
AU2017248353A1 (en) 2018-10-25
SG11201808829VA (en) 2018-11-29
US20220220173A1 (en) 2022-07-14
US20190211070A1 (en) 2019-07-11
US12129285B2 (en) 2024-10-29

Similar Documents

Publication Publication Date Title
CN109563130A (zh) 用于治疗神经退行性疾病的tdp-43线粒体定位抑制剂
JP6640275B2 (ja) グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
JP5645816B2 (ja) 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
Szelechowski et al. A viral peptide that targets mitochondria protects against neuronal degeneration in models of Parkinson’s disease
EA017403B1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
US20240041922A1 (en) Methods and compositions
US10696728B2 (en) Polypeptides, related nucleic acids, and their uses for cell modulation and treatments
EP3583117B1 (en) In vitro method for fusing two or more cells, in vitro, method for delivering a gene of interest, and pharmaceutical composition for use in the treatment of a disease
ITMI20070127A1 (it) Proteine e-o peptidi per la prevenzione e-o cura di malattie neurodegenerative
ES2638370T3 (es) Inhibidores del complejo PP1/GADD34 para el tratamiento de una afección que requiera una actividad inmunosupresora
CN111484977A (zh) 重编程产生功能性去甲肾上腺素能神经元的方法
JPH07509599A (ja) キメラ受容体ポリペプチド，ヒトｈ１３タンパク質，ならびにその使用
US20210310020A1 (en) Adult Stem Cell Line Introduced with Hepatocyte Growth Factor Gene and Neurogenic Transcription Factor Gene with Basic Helix-Loop-Helix Motif and Uses Thereof
US20100111913A1 (en) Method of enhancing migration of neural precursor cells
KR20200053909A (ko) GstO2를 포함하는 신경계 퇴행성 질환 치료용 조성물
Chang Extended amygdala CRH circuits trigger aversive responses
Badillos Rodríguez FAIM-L participation in Alzheimer's Disease and other tauopathies: Deciphering the role of FAIM-L in tau ubiquitination, synaptic maintenance, and memory function during the development of tau pathology
Tu et al. Distinct Flower signaling domains orchestrate cellular fitness via secreted vesicles in Aβ-induced neurodegeneration
Pratelli Ultrastructural and immunolocalization studies on the interactions occurring between IntraFlagellar Transport components and the ciliary tip structures during IFT trains turnaround in Chlamydomonas flagella
Tamim-Yecheskel Characterizing the molecular and physiological role of TECPR2 with an emphasis on neuronal systems
CN115006552A (zh) 基因手段干扰RAP1GDS1、Miro在制备缓解钙超载及线粒体功能药物中的应用
Hua et al. Partial interchangeability ofFz3andFz6in tissue polarity signaling for epithelial orientation and axon growth and guidance
Brown The effects of clusterin on the aggregation and pathogenicity of TDP-43, a protein implicated in amyotrophic lateral sclerosis
Drokhlyansky The Brain Has an Innate Immune Response That Can Limit Virus Spread
JP2005287418A (ja) 細胞殺傷性と細胞死防御性とを併せもつペプチド

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190402

WD01 Invention patent application deemed withdrawn after publication